PReventive Efficacy and Safety of rEbamipide on Nsaid Induced Mucosal Toxicity

Phase

Condition

Musculoskeletal Diseases

Osteoarthritis

Bone Diseases

Treatment

N/A

Clinical Study ID

NCT00576706

037-KOA-0701i

Ages > 19
All Genders

Study Summary

To prove that the efficacy and safety of Mucosta® (Rebamipide) is non-inferior to those of Cytotec® (Misoprostol), in terms of prevention of NSAID-induced gastric ulcer.

Eligibility Criteria

Inclusion

Inclusion Criteria:

Signed written informed consent after being informed of the clinical trial
Males or females 19 years of age
Intake of any brand of NSAIDs in more than half of daily dose for at least theprevious 4 weeks.

Exclusion

Exclusion Criteria:

Necessary to proceed in concomitant treatment with epileptic medications,anti-chollinergics, prokinetics, sucralfate
Presence or history of allergic drug reaction to the following medications;rebamipide, Misoprostol, NSAIDs designated to the protocol

Study Design

December 01, 2007

March 31, 2010

Connect with a study center

Bucheon,
Korea, Republic of
Site Not Available
Chonju,
Korea, Republic of
Site Not Available
Daegu,
Korea, Republic of
Site Not Available
Daejeon,
Korea, Republic of
Site Not Available
Gwangju,
Korea, Republic of
Site Not Available
Incheon,
Korea, Republic of
Site Not Available
Jinju,
Korea, Republic of
Site Not Available
Pusan,
Korea, Republic of
Site Not Available
Seoul,
Korea, Republic of
Site Not Available
Suwon,
Korea, Republic of
Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.